{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:41:41Z","timestamp":1791106901474,"version":"4.1.0"},"reference-count":81,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Targeting angiogenesis has become an established therapeutic approach to fighting solid tumor growth in cancer patients. Even though increased angiogenesis has long been recognized in various types of hematologic malignancies, the molecular basis underlying this angiogenic switch in leukemias remains poorly understood. The BM stroma is gaining increasing attention for its role in promoting leukemia growth and resistance against current treatments with tyrosine kinase inhibitors. This article provides a brief overview of the role of angiogenesis in leukemias, discusses recent insights into the role of placenta growth factor (PlGF), a VEGF family member, as a novel disease candidate in chronic myeloid leukemia (CML), and highlights the therapeutic potential of PlGF blockade for imatinib-resistant CML.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.1","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Angiogenesis: A Target in Solid Tumors, Also in Leukemia?"],"prefix":"10.1182","volume":"2011","author":[{"given":"Thomas","family":"Schmidt","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Carmeliet","sequence":"additional","affiliation":[{"name":"Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center (VRC), VIB, Leuven, Belgium; and"},{"name":"Laboratory of Angiogenesis and Neurovascular Link, VRC, K.U.Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111717073283400_B1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"2019111717073283400_B2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrm2183","article-title":"Molecular regulation of angiogenesis and lymphangiogenesis","volume":"8","author":"Adams","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2019111717073283400_B3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.devcel.2009.01.003","article-title":"Regulation of angiogenesis by oxygen and metabolism","volume":"16","author":"Fraisl","year":"2009","journal-title":"Dev Cell"},{"key":"2019111717073283400_B4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2019111717073283400_B5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1152\/physrev.00031.2008","article-title":"Role and therapeutic potential of VEGF in the nervous system","volume":"89","author":"Ruiz de Almodovar","year":"2009","journal-title":"Physiol Rev"},{"key":"2019111717073283400_B6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","article-title":"Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"key":"2019111717073283400_B7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2019111717073283400_B8","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B9","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"2019111717073283400_B14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"2019111717073283400_B19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2019111717073283400_B21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1947601909356574","article-title":"Mechanisms of resistance to anti- angiogenic therapy and development of third-generation anti-angiogenic drug candidates","volume":"1","author":"Loges","year":"2010","journal-title":"Genes Cancer"},{"key":"2019111717073283400_B22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic therapy: impact on invasion, disease progression and metastasis","volume":"8","author":"Ebos","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111717073283400_B24","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1158\/1535-7163.MCT-08-0182","article-title":"Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib","volume":"7","author":"Padera","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2019111717073283400_B25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2010.30.2794","article-title":"Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials","volume":"29","author":"Miles","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2019111717073283400_B27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"2019111717073283400_B28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell"},{"key":"2019111717073283400_B29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cell.2010.02.039","article-title":"Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease","volume":"141","author":"Van de Veire","year":"2010","journal-title":"Cell"},{"key":"2019111717073283400_B30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","article-title":"HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF","volume":"19","author":"Rolny","year":"2011","journal-title":"Cancer Cell"},{"key":"2019111717073283400_B31","first-page":"349","article-title":"The bone marrow vascular niche: home of HSC differentiation and mobilization","volume":"20","author":"Kopp","year":"2005","journal-title":"Physiology (Bethesda)"},{"key":"2019111717073283400_B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","article-title":"Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches","volume":"12","author":"Konopleva","year":"2009","journal-title":"Drug Resist Updat"},{"key":"2019111717073283400_B33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.leu.2402444","article-title":"Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia","volume":"16","author":"Holyoake","year":"2002","journal-title":"Leukemia"},{"key":"2019111717073283400_B34","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.22180","article-title":"Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts","volume":"119","author":"Hatfield","year":"2006","journal-title":"Int J Cancer"},{"key":"2019111717073283400_B35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.stem.2009.01.006","article-title":"Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells","volume":"4","author":"Hooper","year":"2009","journal-title":"Cell Stem Cell"},{"key":"2019111717073283400_B36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood-2004-11-4269","article-title":"Tie2 activation contributes to hemangiogenic regeneration after myelosuppression","volume":"106","author":"Kopp","year":"2005","journal-title":"Blood"},{"key":"2019111717073283400_B37","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"2019111717073283400_B38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ni1571","article-title":"Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches","volume":"9","author":"Sapoznikov","year":"2008","journal-title":"Nat Immunol"},{"key":"2019111717073283400_B39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2826.2008.01719.x","article-title":"Novel aspects of glutamatergic signalling in the neuroendocrine system","volume":"20","author":"Hrabovszky","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"2019111717073283400_B40","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2002-01-0084","article-title":"Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia","volume":"100","author":"Molica","year":"2002","journal-title":"Blood"},{"key":"2019111717073283400_B41","first-page":"815","article-title":"Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia","volume":"150","author":"Perez-Atayde","year":"1997","journal-title":"Am J Pathol"},{"key":"2019111717073283400_B42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V95.1.309","article-title":"Evidence of increased angiogenesis in patients with acute myeloid leukemia","volume":"95","author":"Hussong","year":"2000","journal-title":"Blood"},{"key":"2019111717073283400_B43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","journal-title":"Am J Pathol"},{"key":"2019111717073283400_B44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"Br J Cancer"},{"key":"2019111717073283400_B45","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064","article-title":"Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma","volume":"93","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"2019111717073283400_B46","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padr\u00f3","year":"2000","journal-title":"Blood"},{"key":"2019111717073283400_B47","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"2019111717073283400_B48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/00365510701854991","article-title":"Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia","volume":"68","author":"Zhelyazkova","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"2019111717073283400_B49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.leu.2402769","article-title":"Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study","volume":"17","author":"Korkolopoulou","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2019111717073283400_B50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.leukres.2009.06.023","article-title":"Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF","volume":"34","author":"Maffei","year":"2010","journal-title":"Leuk Res"},{"key":"2019111717073283400_B51","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2008.07372.x","article-title":"Antiangiogenesis in haematological malignancies","volume":"143","author":"Li","year":"2008","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111717073283400_B52","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2009.175","article-title":"Contribution of bone microenvironment to leukemogenesis and leukemia progression","volume":"23","author":"Ayala","year":"2009","journal-title":"Leukemia"},{"key":"2019111717073283400_B53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1200\/JCO.2005.05.058","article-title":"Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival","volume":"23","author":"Loges","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbrc.2008.03.133","article-title":"Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells","volume":"370","author":"He","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2019111717073283400_B55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2006.11.006","article-title":"Angiogenesis and antiangiogenic therapy in hematologic malignancies","volume":"62","author":"Dong","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019111717073283400_B56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2008.255","article-title":"Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors","volume":"23","author":"Negaard","year":"2009","journal-title":"Leukemia"},{"key":"2019111717073283400_B57","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.V99.7.2532","article-title":"VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition","volume":"99","author":"Dias","year":"2002","journal-title":"Blood"},{"key":"2019111717073283400_B58","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood"},{"key":"2019111717073283400_B59","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.virol.2009.02.036","article-title":"Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses","volume":"387","author":"Nakamura","year":"2009","journal-title":"Virology"},{"issue":"6","key":"2019111717073283400_B60","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3324\/haematol.2010.037689","article-title":"Bevacizumab potentiates chemotherapeutic effect on T-leukemia\/lymphoma cells by direct action on tumor endothelial cells","volume":"96","author":"Wang","year":"2011","journal-title":"Haematologica"},{"key":"2019111717073283400_B61","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2402831","article-title":"Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity","volume":"17","author":"Zhu","year":"2003","journal-title":"Leukemia"},{"key":"2019111717073283400_B62","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1073\/pnas.191117498","article-title":"Inhibition of both paracrine and autocrine VEGF\/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias","volume":"98","author":"Dias","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111717073283400_B63","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.cgt.7700645","article-title":"Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence","volume":"10","author":"He","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"2019111717073283400_B64","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood-2009-06-230474","article-title":"Leukemia regression by vascular disruption and antiangiogenic therapy","volume":"116","author":"Madlambayan","year":"2010","journal-title":"Blood"},{"key":"2019111717073283400_B65","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.leu.2404632","article-title":"Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity","volume":"21","author":"Zahiragic","year":"2007","journal-title":"Leukemia"},{"key":"2019111717073283400_B66","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","article-title":"Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab","volume":"10","author":"Karp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111717073283400_B67","article-title":"VEGF targeted therapy in acute myeloid leukemia. [published online ahead of print October 22, 2010]","author":"Rodriguez-Ariza","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019111717073283400_B68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B69","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111717073283400_B70","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B71","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111717073283400_B72","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019111717073283400_B73","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","article-title":"FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?","volume":"8","author":"Fischer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2019111717073283400_B74","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-08-2276","article-title":"\u201cAntimyeloangiogenic\u201d therapy for cancer by inhibiting PlGF","volume":"15","author":"Loges","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019111717073283400_B75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2013exploring the full potential of targeted therapy for CML","volume":"6","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111717073283400_B76","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"2019111717073283400_B77","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.leukres.2003.10.005","article-title":"Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era","volume":"28","author":"Van Etten","year":"2004","journal-title":"Leuk Res"},{"key":"2019111717073283400_B78","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"2019111717073283400_B79","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nm740","article-title":"Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment","volume":"8","author":"Hattori","year":"2002","journal-title":"Nat Med"},{"key":"2019111717073283400_B80","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood-2005-06-2530","article-title":"VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease","volume":"107","author":"Fragoso","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111717073283400_B81","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/1\/1492799\/bep00111000001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/1\/1492799\/bep00111000001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T22:07:54Z","timestamp":1574028474000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/1\/96426\/Angiogenesis-A-Target-in-Solid-Tumors-Also-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.1","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}